Peptide and Low Molecular Weight Proteins Based Kidney Targeted Drug Delivery Systems

Due to their targeting ability and high degree of safety, Low Molecular Weight Proteins (LMWP) and peptides based kidney-targeted drug delivery systems raise lots of concerns for increasing renal effectiveness and reducing extra-renal toxicity. In general, the accumulation of drug-carrier conjugation in the kidney is associated with its size and charge. After accumulation, the drug need to quantitatively release from the carrier and regenerate the parent drug. Furthermore, the linkage between the drug and carrier can significantly influence the in vivo efficacy of the drug, it is important to employ a proper linkage to achieve a suitable balance between the drug stability in the circulation and intrarenal release rate. Now, most of developed drug-carrier conjugations are tested in vitro or in vivo, but not available in the clinical use. Although much future work remains to do, the prospects are exciting, and the success may be just around the corner.